(1)

Regulation (EU) 2015/2283 provides that only novel foods authorised and included in the Union list may be placed on the market within the Union.

(2)

Pursuant to Article 8 of Regulation (EU) 2015/2283, Commission Implementing Regulation (EU) 2017/2470 (2) establishing a Union list of authorised novel foods was adopted.

(3)

On 31 December 2018, the company Avena Nordic Grain Oy (‘the applicant’) submitted an application to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 to place partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. low cultivars (00), on the Union market as a novel food. The applicant requested for the partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. to be used in cereal bars, muesli and similar mixed breakfast cereals, extruded breakfast cereal products, snacks other than chips and similar, brown gluten-free breads, bread and rolls with special ingredients added, multigrain bread and rolls, meat substitutes, and meat balls.

(4)

The applicant also proposed that, because the protein fraction of the partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. is similar to that of the rapeseed protein authorised as a novel food by Commission Implementing Decision 2014/424/EU (3) for which the European Food Safety Authority (‘the Authority’) had concluded (4) that a risk of sensitisation cannot be excluded and that it is likely that it can trigger allergic reactions in people allergic to mustard, the labelling of food products containing partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. is such to allow people who are allergic to mustard to avoid consumption of those foods.

(5)

On 31 December 2018, the applicant also made a request to the Commission for the protection of proprietary data for a randomised double-blind, controlled, parallel group, 4-week intervention human clinical trial study, to assess the safety and tolerability of the novel food among healthy consumers (5).

(6)

On 19 June 2019, the Commission requested the Authority to carry out an assessment of the partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. as a novel food in accordance with Article 10(3) of Regulation (EU) 2015/2283.

(7)

On 30 June 2020, the Authority adopted its scientific opinion ‘Safety of rapeseed powder from Brassica rapa L. and Brassica napus L. as a novel food pursuant to Regulation (EC) 2015/2283’ (6) in accordance with the requirements of Article 11 of Regulation (EU) 2015/2283.

(8)

In its scientific opinion, the Authority concluded that partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. is safe under the proposed conditions of use. However, it also concluded that the partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. rapeseed may trigger allergic reactions in people allergic to mustard. Therefore, that scientific opinion gives sufficient grounds to establish that partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L., when used in cereal bars, muesli and similar mixed breakfast cereals, extruded breakfast cereal products, snacks other than chips and similar, brown gluten-free breads, bread and rolls with special ingredients added, multigrain bread and rolls, meat substitutes, and meat balls, and provided that the labelling of the foods containing partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. is such to allow people who are allergic to mustard to avoid consumption of those foods, complies with the authorisation requirements of Article 12(1) of Regulation (EU) 2015/2283.

(9)

The opinion of the Authority and the composition and specification data submitted by the applicant also give sufficient grounds to include total carbohydrates in the novel food specification as this is an important nutritional component whose inclusion will complete the proximate profile of this novel food.

(10)

In its scientific opinion, the Authority considered that it could have reached its conclusions on the safety of the partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. under the proposed conditions of use without the data claimed as proprietary by the applicant (a randomised double-blind, controlled, parallel-group, 4-week intervention, human clinical trial study, to assess the safety and tolerability of the novel food among healthy consumers).

(11)

Therefore, the Commission considers that the requirements laid down in Article 26(2) of Regulation (EU) 2015/2283 have not been fulfilled, and the requested protection of the proprietary data included in the application cannot be granted. It is therefore appropriate that the authorisation of the partially defatted rapeseed powder from Brassica rapa L. and Brassica napus L. as a novel food and its inclusion in the Union list of authorised novel foods should contain only the information referred to in Article 9(3) of Regulation (EU) 2015/2283.

(12)

The Annex to Implementing Regulation (EU) 2017/2470 should be therefore be amended accordingly.

(13)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,